EDIT · Editas Medicine, Inc.

Editas Medicine reported a significant year-over-year improvement in its first quarter 2026 financial results, with net loss narrowing to $25.0 million, or $0.26 per share, from $76.1 million, or $0.92 per share, in the prior year period. This substantial reduction in operating loss was primarily driven by a $9.0 million decrease in Research and Development expenses to $17.6 million and the absence of restructuring and impairment charges, which totaled $40.9 million in Q1 2025. The R&D decline specifically reflects reduced headcount and costs associated with the discontinuation of the reni-cel program initiated in December 2024. Collaboration revenue decreased to $2.8 million from $4.7 million, attributed to the conclusion of a strategic partnership agreement.

Operationally, the company is pivoting focus toward its in vivo gene editing candidate EDIT-401 for hyperlipidemia. Management highlighted compelling preclinical data showing >90% mean LDL-C reduction, with plans to initiate a first-in-human clinical trial in patients with Heterozygous Familial Hypercholesterolemia (HeFH) later this year. The company targets early human proof-of-concept data by year-end 2026. Additionally, the U.S. Patent and Trademark Office reaffirmed a decision in favor of the Broad Institute regarding CRISPR/Cas9 interference, securing the intellectual property estate exclusively licensed to Editas. With $123.6 million in cash and equivalents, the company maintains a runway into the third quarter of 2027, supporting the advancement of the EDIT-401 clinical program.